Foghorn Therapeutics Corporate Update and Outlook

 – Initial clinical data for FHD-286 expected in H1’22 and FHD-609 as early as H1’22

– Advancing broad therapeutic pipeline of oncology programs including protein degraders, enzymatic inhibitors and transcription factor disruptors

– Entered strategic collaboration in December 2021 with Loxo Oncology at Lilly for five novel oncology targets using Foghorn’s proprietary Gene Traffic Control® Platform, including $380 million in upfront consideration

– Significant cash runway including $154.3 million in cash, cash equivalents and marketable securities at year end plus the $300 million received in January as part of the Lilly collaboration equating to $454.3 million in pro forma year-end cash, cash equivalents and marketable securities.

https://finance.yahoo.com/news/foghorn-therapeutics-provides-full-2021-120000853.html